Last reviewed · How we verify
Glimepirde
At a glance
| Generic name | Glimepirde |
|---|---|
| Also known as | Amaryl |
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis (NA)
- Endotherapy for Painless Chronic Pancreatitis (NA)
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (PHASE4)
- Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glimepirde CI brief — competitive landscape report
- Glimepirde updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI